cash_cow1 Wednesday, 05/15/19 09:53:40 PM Re: Three2001 post# 2163 Post # of 2222 I call them today and my phone call was returned. I spoke with the representative, ask him if there is any thing the company can do about the share price. They have works in progress but he could not give me any info about it. He said the equipment failure caused the company not to be able to release a more positive earnings report which would had a better out come for the share price. Would've shown a more than double revenue than what was release in the earnings report. Which he stated they explain it in the earnings report. The $600 thousands revenue will be added to 2nd quarter revenue. I asked were everything still on time for the US clinical trial studies, he said yes. The company expect for cGUARD to meet US requirements for FDA approval in the US. That study should be completed by 2020. Ask do they have any plans of selling the company, when it does pass US FDA approval to be sold in the US, he did not commented much on the question, but laugh and sounded very excited about the question.In the US positive clinical trials of devices and drugs which is already on the market in other countries draw in many opportunities of partnering with big drug pharmaceuticals and medical device manufacture companies, and possible buyout opportunities from other device and drug companies and manufactures. He also stated positive clinical trial bring in mutual funds big investors, but not with a $5 million market cap. The company have plans in raising their share price and market cap, but he didn't share the plans with me. One of their big goals is to get FDA approval of the cGUARD device.